Biomarkers /
PR Positive
Back to Biomarkers List
Associated Diseases
Overview
Biomarker-Directed Therapies
PR Positive is a predictive biomarker for use of fulvestrant, aromatase inhibitor, everolimus, exemestane, trastuzumab, anastrozole, letrozole, abemaciclib, endocrine therapy, tamoxifen, alpelisib, lapatinib, palbociclib, ribociclib, ado-trastuzumab emtansine, ivosidenib, pertuzumab, and toremifene in patients.
Of the therapies with PR Positive as a predictive biomarker, 13 are FDA-approved and 17 have NCCN guidelines in at least one clinical setting.
Breast carcinoma and breast invasive lobular carcinoma have the most therapies targeted against PR Positive or its related pathways [5].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Anastrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NICE, SMC) | |
| Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR). |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for metastatic disease. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, and for HR-positive advanced disease with progression following endocrine therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Ivosidenib +
Breast Invasive Lobular Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Sensitive |
| Clinical Setting(s): Metastatic (BNF) |
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for advanced breast cancer as first-line treatment or after progression following antiestrogen therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR+ breast cancer, both as adjuvant treatment and in the metastatic setting. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE) |
Toremifene +
Breast Carcinoma -
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Clinical Trials
PR Positive serves as an inclusion eligibility criterion in 342 clinical trials, of which 259 are open and 83 are closed. Of the trials that contain PR Positive as an inclusion criterion, 7 are early phase 1 (5 open), 67 are phase 1 (54 open), 36 are phase 1/phase 2 (28 open), 146 are phase 2 (105 open), 4 are phase 2/phase 3 (3 open), 53 are phase 3 (42 open), 6 are phase 4 (2 open), and 23 are no phase specified (20 open).
Trials with PR Positive in the inclusion eligibility criteria most commonly target breast carcinoma, invasive breast carcinoma, breast adenocarcinoma, breast invasive ductal carcinoma, and ductal carcinoma in situ [5].
Fulvestrant, letrozole, palbociclib, placebo, and abemaciclib are the most frequent therapies in trials with PR Positive as an inclusion criteria [5].
Significance of PR Positive in Diseases
Breast Carcinoma +
PR Positive is an inclusion criterion in 288 clinical trials for breast carcinoma, of which 210 are open and 78 are closed. Of the trials that contain PR Positive and breast carcinoma as inclusion criteria, 6 are early phase 1 (4 open), 62 are phase 1 (50 open), 31 are phase 1/phase 2 (24 open), 122 are phase 2 (82 open), 4 are phase 2/phase 3 (3 open), 42 are phase 3 (32 open), 6 are phase 4 (2 open), and 15 are no phase specified (13 open) [5].
Letrozole, anastrozole, fulvestrant, exemestane, everolimus, tamoxifen, alpelisib, aromatase inhibitor, trastuzumab, abemaciclib, ribociclib, palbociclib, endocrine therapy, pertuzumab, lapatinib, ado-trastuzumab emtansine, and toremifene have evidence of efficacy in patients with PR Positive in breast carcinoma [5].
Breast Invasive Lobular Carcinoma +
PR Positive is an inclusion criterion in 3 clinical trials for breast invasive lobular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PR Positive and breast invasive lobular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Ivosidenib has evidence of efficacy in patients with PR Positive in breast invasive lobular carcinoma [5].
Malignant Solid Tumor +
PR Positive is an inclusion criterion in 26 clinical trials for malignant solid tumor, of which 22 are open and 4 are closed. Of the trials that contain PR Positive and malignant solid tumor as inclusion criteria, 19 are phase 1 (16 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].
Invasive Breast Carcinoma +
PR Positive is an inclusion criterion in 19 clinical trials for invasive breast carcinoma, of which 18 are open and 1 is closed. Of the trials that contain PR Positive and invasive breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 5 are phase 3 (5 open), and 1 is no phase specified (1 open) [5].
Breast Adenocarcinoma +
PR Positive is an inclusion criterion in 16 clinical trials for breast adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain PR Positive and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 4 are phase 2 (4 open), 6 are phase 3 (5 open), and 3 are no phase specified (3 open) [5].
Ovarian Carcinoma +
PR Positive is an inclusion criterion in 15 clinical trials for ovarian carcinoma, of which 11 are open and 4 are closed. Of the trials that contain PR Positive and ovarian carcinoma as inclusion criteria, 9 are phase 1 (6 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].
Non-Small Cell Lung Carcinoma +
PR Positive is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 8 are open and 1 is closed. Of the trials that contain PR Positive and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open) and 3 are phase 2 (2 open) [5].
Colorectal Carcinoma +
PR Positive is an inclusion criterion in 8 clinical trials for colorectal carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PR Positive and colorectal carcinoma as inclusion criteria, 7 are phase 1 (6 open) and 1 is phase 1/phase 2 (1 open) [5].
Fallopian Tube Carcinoma +
PR Positive is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PR Positive and fallopian tube carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].
Primary Peritoneal Carcinoma +
PR Positive is an inclusion criterion in 8 clinical trials for primary peritoneal carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PR Positive and primary peritoneal carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].
Endometrial Carcinoma +
PR Positive is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PR Positive and endometrial carcinoma as inclusion criteria, 4 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
PR Positive is an inclusion criterion in 7 clinical trials for prostate carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PR Positive and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].
Breast Invasive Ductal Carcinoma +
PR Positive is an inclusion criterion in 5 clinical trials for breast invasive ductal carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PR Positive and breast invasive ductal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are no phase specified (1 open) [5].
Cervical Carcinoma +
PR Positive is an inclusion criterion in 5 clinical trials for cervical carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PR Positive and cervical carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (1 open) [5].
Ductal Carcinoma In Situ +
PR Positive is an inclusion criterion in 5 clinical trials for ductal carcinoma in situ, of which 4 are open and 1 is closed. Of the trials that contain PR Positive and ductal carcinoma in situ as inclusion criteria, 2 are phase 2 (1 open) and 3 are no phase specified (3 open) [5].
Small Cell Lung Carcinoma +
PR Positive is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PR Positive and small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [5].
Urothelial Carcinoma +
PR Positive is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR Positive and urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (3 open) [5].
Endometrial Endometrioid Adenocarcinoma +
PR Positive is an inclusion criterion in 4 clinical trials for endometrial endometrioid adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PR Positive and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [5].
Melanoma +
PR Positive is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain PR Positive and melanoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].
Non-Hodgkin Lymphoma +
PR Positive is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain PR Positive and non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
PR Positive is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain PR Positive and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].
Endometrial Mixed Adenocarcinoma +
PR Positive is an inclusion criterion in 3 clinical trials for endometrial mixed adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR Positive and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].
Prostate Adenocarcinoma +
PR Positive is an inclusion criterion in 3 clinical trials for prostate adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR Positive and prostate adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].
Biliary Tract Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for biliary tract carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Cancer +
PR Positive is an inclusion criterion in 2 clinical trials for cancer, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and cancer as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Endometrial Clear Cell Adenocarcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for endometrial clear cell adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and endometrial clear cell adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Endometrial Serous Adenocarcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and endometrial serous adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Endometrial Undifferentiated Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for endometrial undifferentiated carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and endometrial undifferentiated carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Gastric Adenocarcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and gastric adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Gastric Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Glioblastoma +
PR Positive is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Hepatocellular Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Lung Adenocarcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Medullary Breast Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for medullary breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and medullary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Positive and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Renal Cell Carcinoma +
PR Positive is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain PR Positive and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].
Adenoid Cystic Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Anaplastic Astrocytoma +
PR Positive is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Bladder Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Breast Lobular Carcinoma In Situ +
PR Positive is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and breast lobular carcinoma in situ as inclusion criteria, 1 is no phase specified (1 open) [5].
Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Clear Cell Renal Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Colon Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and colon carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Desmoid-Type Fibromatosis +
PR Positive is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1 (1 open) [5].
Endometrial Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Dedifferentiated Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrial dedifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrial dedifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Mucinous Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrial mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrial mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Squamous Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrial squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrial squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Transitional Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrial transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrial transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrioid Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Esophageal Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gastrointestinal Neuroendocrine Tumors +
PR Positive is an inclusion criterion in 1 clinical trial for gastrointestinal neuroendocrine tumors, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and gastrointestinal neuroendocrine tumors as inclusion criteria, 1 is phase 2 (1 open) [5].
Hypopharyngeal Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Inflammatory Breast Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for inflammatory breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and inflammatory breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Invasive Papillary Breast Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for invasive papillary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and invasive papillary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Laryngeal Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Liposarcoma +
PR Positive is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Low Grade Ovarian Serous Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lung Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lung Neuroendocrine Neoplasm +
PR Positive is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Lymphoma +
PR Positive is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Malignant Ovarian Serous Tumor +
PR Positive is an inclusion criterion in 1 clinical trial for malignant ovarian serous tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
PR Positive is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Mixed Lobular And Ductal Breast Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for mixed lobular and ductal breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Mucinous Breast Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and mucinous breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Neuroendocrine Tumor +
PR Positive is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Non-Clear Cell Renal Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Oral Cavity Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Oropharyngeal Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Endometrioid Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Epithelial Tumor +
PR Positive is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Granulosa Cell Tumor +
PR Positive is an inclusion criterion in 1 clinical trial for ovarian granulosa cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and ovarian granulosa cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Neuroendocrine Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and pancreatic neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Neuroendocrine Neoplasm +
PR Positive is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR Positive and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Pancreatic Neuroendocrine Tumor +
PR Positive is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and pancreatic neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Peritoneal Mesothelioma +
PR Positive is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Primary Peritoneal Serous Adenocarcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Undifferentiated Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR Positive and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Sarcoma +
PR Positive is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Transitional Cell Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Tubular Breast Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for tubular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and tubular breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ureter Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Uterine Sarcoma +
PR Positive is an inclusion criterion in 1 clinical trial for uterine sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and uterine sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vaginal Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vulvar Carcinoma +
PR Positive is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Positive and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
